DocDollars

Calliditas Therapeutics Us Inc.

NJ · United States · Reporting entity ID 100001176934

Total reported 2019–2025
$6.22M
#636 of 2,960 reporting companies — 0% of all reported industry payments
$5.55M in general payments across 40,694 records, plus $674K in research funding across 69 records.

How it breaks down

General payments $5,549,227
Research funding $673,546

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Calliditas Therapeutics Us Inc. reported $6.22M to US doctors and teaching hospitals from 2019 to 2025, ranking #636 of 2,960 reporting companies. 11% of that was research funding and 89% general payments such as consulting, speaking, food and travel. 40,694 general payment records and 69 research records were filed.

Common questions about Calliditas Therapeutics Us Inc.

How much has Calliditas Therapeutics Us Inc. paid US doctors?

Calliditas Therapeutics Us Inc. reported $6,222,773 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $5,549,227 in general payments, $673,546 in research funding.

How does Calliditas Therapeutics Us Inc. rank among drug and device companies?

It ranks #636 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Calliditas Therapeutics Us Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.